Dahoun, T
Trossbach, S V
Brandon, N J
Korth, C
Howes, O D
Article History
Received: 21 July 2016
Revised: 16 November 2016
Accepted: 27 November 2016
First Online: 31 January 2017
Competing interests
: NJB is a full-time employee and a shareholder in AstraZeneca plc. ODH has received investigator-initiated research funding from and/or participated in advisory/speaker meetings organised by AstraZeneca, Autifony, BMS, Eli Lilly, Heptares, Jansenn, Lundbeck, Lyden-Delta, Otsuka, Servier, Sunovion, Rand and Roche. The remaining authors declare no conflict of interest.